Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.34 |
| ▸ | LATS1 | O95835 | 3/20 | 0.34 |
| ▸ | LATS2 | Q9NRM7 | 3/20 | 0.34 |
| ▸ | PRKCB | P05771 | 1/20 | 0.34 |
| ▸ | PRKCH | P24723 | 1/20 | 0.34 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.34 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.34 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.33 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30211245 | 1.00 | LOXL2 (0.39) | LOXL2PDE4BPDE7AUSP2RAB9A | |
| SCHEMBL803091 | 0.83 | LOXL2 (0.42) | LOXL2RAB9ALATS1LATS2PRKCB | |
| SCHEMBL30947591 | 0.81 | LOXL2 (0.41) | LOXL2LATS1LATS2PRKCBPRKCH | |
| SCHEMBL9667063 | 0.80 | SLC22A12 (0.41) | SLC22A12CYP3A4 | |
| SCHEMBL31407209 | 0.79 | LOXL2 (0.44) | LOXL2LATS1LATS2PRKCBPRKCH | |
| SCHEMBL27842129 | 0.77 | TDP1 (0.38) | LATS1LATS2PRKCHPRKCEPRKCQ | |
| SCHEMBL31291226 | 0.77 | TDP1 (0.38) | LATS1LATS2PRKCHPRKCEPRKCQ | |
| SCHEMBL18626326 | 0.76 | LOXL2 (0.41) | LOXL2PDE4BPDE7ALATS1LATS2 | |
| SCHEMBL2145747 | 0.76 | LOXL2 (0.43) | LOXL2 | |
| SCHEMBL3379818 | 0.75 | ALDH1A1 (0.42) | MAPTGSK3BSLC22A12CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024010963-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2024-01-11 | — | — | WO | disclosed |
| US-9663511-B2 | Sphingosine 1-phosphate receptor antagonists | Arroyo BioSciences, LLC (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663511-B2 | Sphingosine 1-phosphate receptor antagonists | Arroyo BioSciences, LLC (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150045332-A1 | Novel Sphingosine 1-Phosphate Receptor Antagonists | ARROYO BIOSCIENCES L.L.C. | 2015-02-12 | — | — | US | disclosed |
| US-20150045332-A1 | Novel Sphingosine 1-Phosphate Receptor Antagonists | ARROYO BIOSCIENCES L.L.C. | 2015-02-12 | — | — | US | disclosed |
| US-8703797-B2 | Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (S1P2) receptors | ALLERGAN, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130296361-A1 | Condensed Ring Pyridine Compounds As Subtype-Selective Modulators Of Sphingosine-1-Phosphate-2 (S1P2) Receptors | ALLERGAN, INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130296361-A1 | Condensed Ring Pyridine Compounds As Subtype-Selective Modulators Of Sphingosine-1-Phosphate-2 (S1P2) Receptors | ALLERGAN, INC. | 2013-11-07 | — | — | US | disclosed |
| US-20130296361-A1 | Condensed Ring Pyridine Compounds As Subtype-Selective Modulators Of Sphingosine-1-Phosphate-2 (S1P2) Receptors | ALLERGAN, INC. | 2013-11-07 | — | — | US | disclosed |
| US-8507682-B2 | Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (S1P2) receptors | ALLERGAN, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507682-B2 | Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (S1P2) receptors | ALLERGAN, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507682-B2 | Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (S1P2) receptors | ALLERGAN, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| CN-102741232-A | As sphingosine-1-phosphate-2 (S1P)2) Fused ring pyridine compounds as subtype-selective modulators of receptors | ALLERGAN INC | 2012-10-17 | — | — | CN | disclosed |
| US-20120208840-A1 | Condensed Ring Pyridine Compounds As Subtype-Selective Modulators Of Sphingosine-1-Phosphate-2 (S1P2) Receptors | ALLERGAN, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208840-A1 | Condensed Ring Pyridine Compounds As Subtype-Selective Modulators Of Sphingosine-1-Phosphate-2 (S1P2) Receptors | ALLERGAN, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208840-A1 | Condensed Ring Pyridine Compounds As Subtype-Selective Modulators Of Sphingosine-1-Phosphate-2 (S1P2) Receptors | ALLERGAN, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2483245-A1 | CONDENSED RING PYRIDINE COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-2 (S1P2) RECEPTORS | Allergan, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011041287-A1 | CONDENSED RING PYRIDINE COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-2 (S1P2) RECEPTORS | ALLERGAN, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011041287-A1 | CONDENSED RING PYRIDINE COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-2 (S1P2) RECEPTORS | ALLERGAN, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045332-A1 | Novel Sphingosine 1-Phosphate Receptor Antagonists | S1PR2, S1PR1, S1PR5 | LOXL2 723/4885PDE4B 1642/4885PDE7A 1831/4885 |
| US-20130296361-A1 | Condensed Ring Pyridine Compounds As Subtype-Selective Modulators Of Sphingosine-1-Phosphate-2 (S1P2) Receptors | S1PR1, S1PR2, S1PR3 | LOXL2 504/4885PDE4B 418/4885PDE7A 525/4885 |
| US-20120208840-A1 | Condensed Ring Pyridine Compounds As Subtype-Selective Modulators Of Sphingosine-1-Phosphate-2 (S1P2) Receptors | S1PR1, S1PR2, S1PR3 | LOXL2 504/4885PDE4B 418/4885PDE7A 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.